Jonathan French, Sc.D.

Group Leader, Fellow I

Jonathan has over 10 years of drug development experience. He began his career as a project statistician; designing, analyzing and interpreting clinical trials in depression and ADHD. His primary areas of expertise range from model-based meta-analysis and applied Bayesian methods to modeling time-to-event data and missing data mechanisms.

Recent publications by this scientist

Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor (TGCT)

October 12, 2021

Yin, O., Zahir, H., French, J., Polhamus, D., Wang, X., van de Sande, M., Tap, W.D., Gelderblom, H., Wagner, A.J., Healey, J.H., Greenberg, J., Shuster, D. and Stacchiotti, S. Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor (TGCT). CPT: Pharmacometrics & Systems Pharmacology. Advance online publication. https://doi.org/10.1002/psp4.12712

View More

CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision.

July 10, 2021

Rowland Yeo K, Hennig S, Krishnaswami S, Strydom N, Ayyar VS, French J, Sinha V, Sobie E, Zhao P, Friberg LE, Mentré F.
CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):649-657. doi: 10.1002/psp4.12680.

View More

Welcome to the statistics and pharmacometrics themed issue

April 13, 2021

French, J. and Mentré, F. (2021). CPT Pharmacometrics Syst. Pharmacol., 10: 273-274. https://doi.org/10.1002/psp4.12625

View More